Drug news
FDA approves Cimzia for Psoriatic Arthritis
UCB announced that the FDA has on 30 September 2013 approved Cimzia (certolizumab pegol) for the treatment of adult patients with active Psoriatic Arthritis (PsA).
The RAPID-PsA study supporting the US approval is the first randomized, controlled study of an anti-TNF in PsA to include patients with and without prior anti-TNF exposure. The ACR20 results showed that Cimzia rapidly improved the signs and symptoms of PsA for patients with response observed as early as the first week of treatment for some patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins